TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04212052

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: consolidation immunotherapy
Description: Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
Study: NCT02268448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study: NCT02158234

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
Study: NCT02201238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: Diclofenac sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac sodium
Study: NCT03363958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning with Postconditioning
Description: Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC procedure
Description: Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
Study: NCT04444388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa
Description: Sachets of 5 grams of cocoa daily supplementation
Study: NCT02268448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study: NCT01338935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CW 002
Description: In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.
Study: NCT01183312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Sublingual flumazenil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Sublingual flumazenil
Study: NCT00201981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: 1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: 1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
Study: NCT01388868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOF count guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
Study: NCT02201238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Diclofenac sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium
Description: Diclofenac sodium
Study: NCT01388868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T1/ T0 guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2/ T0 guided adjustment
Description: adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
Study: NCT03046160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (Mobilization with movement)
Description: grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
Study: NCT04444388

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachets of 5 grams of maltodextrin daily supplementation
Study: NCT03678051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+CBT4CBT
Description: 45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
Study: NCT03046160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck and scapular exercises.
Description: A program of 12 neck and scapular exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neck and scapular exercises.
Description: A program of 12 neck and scapular exercises.
Study: NCT04232943

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine (IPV)
Description: IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (IPV)
Description: IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)
Description: LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Oral Polio Vaccine (bOPV)
Description: Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3.
Study: NCT06004206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nPSV and PSV
Description: Ventilation with neurally adjusted modes or pressure support modes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nPSV and PSV
Description: Ventilation with neurally adjusted modes or pressure support modes
Study: NCT03420937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine, Atropin Biotika
Description: Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
Study: NCT02955238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum.
Study: NCT02964806

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ordinary Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Modified Atkin's Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketogenic Diet
Study: NCT03971175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps biopsy
Description: Endobronchial biopsy with the forceps

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: Endobronchial biopsy with the cryobiopsy probe
Study: NCT02575443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (MB group)
Description: Count of train-of-four: 1-2 Titration of rocuronium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (DB group)
Description: Post-tetanic count: 1-2 Titration of rocuronium dose
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT04231097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBCT intervention for ACS patients
Description: The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
Study: NCT01773954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: Increased or decreased time between visits
Study: NCT00507585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
Study: NCT03046160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corrective tape
Description: elastic tape used to correct the anterior tilt of the scapula
Study: NCT02201238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Menthol
Study: NCT03046160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective tape
Description: elastic tape used to correct the anterior tilt of the scapula
Study: NCT02044796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT00507585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
Study: NCT02044796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT00063635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg, twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: 400 IU, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Twice daily
Study: NCT04067427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental training
Description: App-based mental training
Study: NCT04995705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a psychological intervention. ACT encourages individuals to remain open to internal experiences (positive, negative and neutral), rather than attempting to control or ameliorate them (which may only serve to increase pain and suffering). It also encourages individuals to focus on committing to a life that is congruent with their core values, regardless of the experiences that show up for them. The premise of this model is to learn to modify the relationship one has with their internal experiences (thoughts, feelings, physical sensations etc.), rather than change the experiences per se. This is achieved through different processes including mindfulness, acceptance, defusion and exploration of values. These core tenets of ACT help to cultivate psychological flexibility.~This ACT intervention is delivered as a 5-week group for stroke survivors and adults with brain injury. It comprises of experiential and didactic components.
Study: NCT03895723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and robotic liver resection
Description: laparoscopic and robotic procedure for liver resection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open surgery
Description: using open surgery procedure for liver resection
Study: NCT02715583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Acetate
Study: NCT02080286

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prism Adaptation
Description: All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism Adaptation
Description: All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prism Adaptation
Description: All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy.
Study: NCT04183946

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online Cognitive Behavioural Therapy
Description: The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script.
Study: NCT02881983

Intervention type: OTHER
Intervention: the presentation of pictures (static stimuli) or videos (dynamic stimuli)

Intervention type: OTHER
Intervention: the presentation of pictures (static stimuli) or videos (dynamic stimuli)
Study: NCT00507585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).